# Dapagliflozin for Cardio-renal Protection After ICU Discharge

Study · id `cardio:ct-nct07025629` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07025629](<https://clinicaltrials.gov/study/NCT07025629>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07025629

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 600 participants.

## Technical summary

Registry record NCT07025629. Randomized; double masking; primary purpose treatment. Start 2025-12-02 (actual); primary completion 2029-01-15 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 600 participants (planned count; ClinicalTrials.gov record NCT07025629, source copy `cardio:ctgov-nct07025629-2026-02-23`, retrieved 2026-10-26)
- Started: 2025-12-02 (actual) (ClinicalTrials.gov record NCT07025629, source copy `cardio:ctgov-nct07025629-2026-02-23`, retrieved 2026-10-26)
- Primary completion: 2029-01-15 (anticipated) (ClinicalTrials.gov record NCT07025629, source copy `cardio:ctgov-nct07025629-2026-02-23`, retrieved 2026-10-26)
- Completion: 2029-01-15 (anticipated) (ClinicalTrials.gov record NCT07025629, source copy `cardio:ctgov-nct07025629-2026-02-23`, retrieved 2026-10-26)
- Countries: France (ClinicalTrials.gov record NCT07025629, source copy `cardio:ctgov-nct07025629-2026-02-23`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07025629-2026-02-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: Dapagliflozin for Cardio-renal Protection After ICU Discharge
- Acronym: DAPA-ICU
- Condition: Heart Failure and Chronic Kidney Disease Post-ICU
- Intervention (Drug): Dapagliflozin 10 MG Oral Tablet \[Farxiga\]
- Intervention (Drug): One tablet of placebo of dapagliflozin 10 mg
- Lead sponsor: Assistance Publique - Hôpitaux de Paris
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Dapagliflozin (Farxiga) (`cardio:farxiga`)
- Registry intervention name is a brand that an FDA record in the corpus ties to this substance: Dapagliflozin (`cardio:dapagliflozin`)
- Registry intervention is a member of this class by a sourced record link: SGLT2 inhibitors (drug class) (`cardio:sglt2-inhibitors`)
- Registry lists this organization as the lead sponsor: Assistance Publique - Hôpitaux de Paris (`cardio:org-assistance-publique-hopitaux-de-paris`)

## Provenance

Content hash: 09dcb08d4b31a161fdc3b12ef1cdd08aee0d7ac951059cc416e5fe04387f4319
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
